| Ytd | -67.99% | |
| 1y | -79.93% |
| Open | 2.17 | Prev Close | 2.17 | Low | 2.14 | High | 2.24 | Mkt Cap | 6.72M |
| Vol | 22.55K | Avg Vol | 77.97K | EPS | -5.63 | P/E | -0.39 | Forward P/E | -3.02 |
| Beta | 1.73 | Short Ratio | 1.17 | Inst. Own | 4.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-21 | 50-d Avg | 3.85 | 200-d Avg | 7.35 | 1yr Est | 35.67 |
CVKD News
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative c
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis,
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis,
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhib
Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhib
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to
New high-value indication for Phase 3-ready asset with data intended to support clinical development
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a la
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a la
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 dat
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Ca
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indicatio
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a significant decreas
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a backgroun
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a large growth in sho
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a bioph
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of t
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they s
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In